Publication | Closed Access
209P Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors
26
Citations
0
References
2021
Year
Sbt6050 MonotherapyMedicineImmunologyPathologyImmune Checkpoint InhibitorInterim ResultsCancer TreatmentOncologyRadiation OncologyPhase I/ib Study
No additional data available for this publication yet. Check back later!